|drug3547||Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki||1.00|
|drug3552||Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki||1.00|
|drug3551||Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki||1.00|
There is one clinical trial.
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
Description: Subject clinical status using the 7-point Ordinal Scale, specified as the primary endpoint in the WHO Master Protocol on day 15 as compared to baseline (1 - Not hospitalized, no limitations on activities; 2 - Not hospitalized, limitation on activities; 3 - Hospitalized, not requiring supplemental oxygen; 4 - Hospitalized, requiring supplemental oxygen; 5 - Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6 - Hospitalized, on invasive mechanical ventilation or ЕСМО; 7 - Death).Measure: Clinical status of the patient (according to 7-point ordinal scale) Time: Day 15
Description: Ordinal scale score status, time to improvementMeasure: Clinical status of the patient (according to Ordinal scale) Time: Days 1 - 29.
Description: NEWS scale score status, time to improvementMeasure: Clinical status of the patient (according to NEWS scale) Time: Days 1 - 29.
Description: Oxygen blood saturationMeasure: Oxygen saturation Time: Days intervals 1-2, 3-5, 6-8, 9-10, 11-12, 13-14, 15-17.
Description: Duration of hospitalizationMeasure: Hospitlization duration Time: Days 1 - 29
Description: Incidence of mortalityMeasure: Mortality Time: Days 1 - 29.
Description: Cumulative incidence of SAEMeasure: Incidence of serious adverse events Time: Days 1 - 29.
Description: Cumulative incidence of AEMeasure: Incidence of adverse events Time: Days 1 - 29.
Description: Permament or temporary discontinuation of infusions or injectionsMeasure: Incidence of discontinuation of drug administration Time: Days 1 - 17.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports